J&J(US:JNJ) 智通财经网·2025-11-27 00:01Core Viewpoint - Johnson & Johnson (JNJ) reached a market capitalization of $500 billion, driven by investor confidence in the company's strategies to address the decline in sales of its psoriasis treatment drug, Stelara [1][4]. Group 1: Stock Performance - On Wednesday, JNJ's stock price rose by 0.4% to $207.56, marking its first close above $500 billion [1]. - The stock has increased for 13 consecutive trading days, the longest streak in the company's history, with a 9.9% rise in November, potentially leading to its best monthly performance since April 2020 [1][4]. - JNJ's stock has risen 44% this year, aiming for its best annual performance since 1995 after experiencing consecutive declines in 2023 and 2024 [4]. Group 2: Analyst Sentiment - Wall Street is optimistic about JNJ's plans to fill the revenue gap following Stelara's patent expiration, focusing on new drugs and acquisitions [1][4]. - Over half of the 30 analysts tracking JNJ still rate the stock as a "buy," despite expectations of limited price upside in the next 12 months, with a target price around $205 [4]. - Scotiabank analyst Louise Chen highlighted JNJ's strong execution and growth potential, giving it the highest target price and designating it as a "preferred stock" [5]. Group 3: Industry Trends - Investors are shifting funds from high-risk sectors to more defensive areas, with the healthcare sector in the S&P 500 rising by 9.7% this month, the largest monthly gain since April 2020 [6]. - The pharmaceutical sector within the S&P 500 has also seen a rise of approximately 17% in November, potentially achieving its best monthly performance ever [6]. - The surge in pharmaceutical stocks is attributed to companies like Eli Lilly (LLY) and Merck (MRK), which have seen significant stock price increases and positive investor sentiment due to recent acquisitions and successful clinical trials [6].